Cytotheryx Secures $60M Funding Round for Liver Disease Treatments

Cytotheryx, a preclinical cell therapy company developing treatments for liver disease, is receiving $60 million in Series A funding. The financing round will be led by Ouroboros Family Founders Fund I.

Cytotheryx is a “spinout,” according to the company, of the Mayo Clinic, located in Rochester, Minn.

Ouroboros said it selected Cytotheryx for its proprietary bio-incubator platform and ability to produce scalable and functional human hepatocytes.

Cytotheryx’s Liver Disease Expertise

Cytotheryx’s bio-incubator platform can produce liver cells at scale. It also provides a bioartificial liver support system in cases of acute failure, and universal liver cells for transplantation.

Revealed during the 2025 Biotech Showcase in San Francisco, the investment is intended to accelerate several programs toward clinical development. It will also expand manufacturing infrastructure and support regulatory pathway planning.

In accordance with this, Cytotheryx also announced debt financing. This allows the company to expand its brick-and-mortar footprint and enhance good manufacturing practice (GMP) manufacturing capability.

“We are pleased to partner with Ouroboros as we advance our cell therapy platform toward the clinic,” Cytotheryx CEO John R. Swart, PhD, said. “This financing provides the resources necessary to scale our manufacturing capabilities and progress multiple programs through critical development milestones.”

“Cytotheryx represents a high-impact healthcare investment opportunity with substantial commercial potential,” Richard Tannenbaum, Managing Partner at Ouroboros Family Founders Fund, said. “The company has developed a differentiated technology platform that addresses a significant clinical need with limited existing solutions.”

Why the Funding is Important

Despite the challenges of the biotech investment climate, investor interest in next-generation cell and gene therapy platforms continues. Ouroboros said the financing validates that interest.

Ouroboros said that subject to closing, the fund will provide a strategic advisory role through the development cycle.